Núñez, K.G.; Sandow, T.; Grahovac, A.; Vallejo-Calzada, R.; Gimenez, J.; Bohorquez, H.; Cohen, A.; Mizrahi, J.; Du, L.; Thevenot, P.
Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes. Cancers 2025, 17, 2745.
https://doi.org/10.3390/cancers17172745
AMA Style
Núñez KG, Sandow T, Grahovac A, Vallejo-Calzada R, Gimenez J, Bohorquez H, Cohen A, Mizrahi J, Du L, Thevenot P.
Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes. Cancers. 2025; 17(17):2745.
https://doi.org/10.3390/cancers17172745
Chicago/Turabian Style
Núñez, Kelley G., Tyler Sandow, Alexandre Grahovac, Ricardo Vallejo-Calzada, Juan Gimenez, Humberto Bohorquez, Ari Cohen, Jonathan Mizrahi, Lingling Du, and Paul Thevenot.
2025. "Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes" Cancers 17, no. 17: 2745.
https://doi.org/10.3390/cancers17172745
APA Style
Núñez, K. G., Sandow, T., Grahovac, A., Vallejo-Calzada, R., Gimenez, J., Bohorquez, H., Cohen, A., Mizrahi, J., Du, L., & Thevenot, P.
(2025). Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes. Cancers, 17(17), 2745.
https://doi.org/10.3390/cancers17172745
